Ines Rombach
Senior Medical Statistician
Passionate about improving the handling and reporting of missing data in randomised controlled trials
As a statistician within the Oxford Clinical Trials Research Unit (OCTRU), I am involved in all aspects of clinical trials.
I contribute statistical expertise to the development of grant applications and to the planning, conduct and analysis of primarily orthopaedic, surgical and antimicrobial trials.
I also hold a researcher post in the Health Economic Research Centre (HERC), where I work on cost-effectiveness analyses alongside randomised controlled trials.
My research interests include the handling and reporting of missing data in randomised clinical trials, the use of patient reported outcomes and surgical trials methodology.
I have been involved in Data Monitoring and Safety Committees as the independent statistician and regularly teach a variety of topics, including aspects of clinical trial design, statistical concepts and statistical programming in Stata.
Recent publications
Exercise therapy with or without other physical therapy interventions versus placebo interventions for osteoarthritis -Systematic review.
Journal article
Dean BJF. et al, (2021), Osteoarthr Cartil Open, 3
The clinical and cost effectiveness of splints for thumb base osteoarthritis: a randomized controlled clinical trial.
Journal article
Adams J. et al, (2021), Rheumatology (Oxford), 60, 2862 - 2877
Study of Peri-Articular Anaesthetic for Replacement of the Knee (SPAARK): statistical analysis plan for a randomised controlled trial assessing the effectiveness of peri-articular liposomal bupivacaine plus bupivacaine hydrochloride compared with bupivacaine hydrochloride alone.
Journal article
Stokes JR. et al, (2021), Trials, 22
Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer's disease scale: development and results from a mapping study.
Journal article
Rombach I. et al, (2021), Qual Life Res, 30, 867 - 879
Personalised high tibial osteotomy has mechanical safety equivalent to generic device in a case-control in silico clinical trial.
Journal article
MacLeod AR. et al, (2021), Commun Med (Lond), 1